PVAM
AXSM icon

Pacific View Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Pacific View Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-39,921
Closed -$568K – 52
2019
Q1 		$568K Buy
+39,921
New +$371K 0.59% 38

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Pacific View Asset Management's AXSM Position: Q2 2019 in Review

Pacific View Asset Management sold out of Axsome Therapeutics (AXSM) in Q2 2019, closing a stake of 39,921 shares — an estimated $568K sold.

Pacific View Asset Management first reported a position in AXSM in Q1 2019 and held it in 1 quarter. The position peaked at $568K in Q1 2019. 109 funds tracked by Wall St. Rank hold AXSM as of Q2 2019.

  • Pacific View Asset Management reported no remaining Axsome Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Pacific View Asset Management sold 39,921 Axsome Therapeutics shares in Q2 2019, an estimated $568K.
  • Pacific View Asset Management first reported a position in Axsome Therapeutics in Q1 2019 and held it in 1 quarter.
  • Pacific View Asset Management's Axsome Therapeutics position peaked at $568K in Q1 2019.
  • 109 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2019.

Based on Pacific View Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.